Share

EORTC presents at San Antonio Breast Cancer Symposium

The EORTC will present five abstracts at San Antonio Breast Cancer Symposium (SABCS) from 5 to 9 December 2017. Find when and where below:

Poster Presentation

  • Quality of life (QoL) in male breast cancer (BC): Prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International male BC program

Time: Friday, December 8, 5:00 pm – 7:00 pm
Location: P5-23-02
Authors: Schroder C, Cardoso F, Dijkstra N, van Leeuwen-Stok E, Linderholm B, Morgenstern D, Van Poznak C, Wolff A, Poncet C, Gomez HL, Aalders K, Bjelic-Radisic V, Werutsky G, Tryfonidis K, Coens C, Giordano SH, Ruddy KJ.

  • Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registry

Time: Friday, December 8, 5:00 pm – 7:00 pm
Location: P5-23-01
Authors: Giordano SH, Schröder CP, Poncet C, van Leeuwen-Stok E, Linderholm B, Abreu MH, Rubio I, Van Poznak C, Morganstern D, Cameron D, Vleugel MM, Smilde TJ, Bozovic-Spasojevic I, Korde L, Russell NS, den Hoed IDM, Honkoop AH, van der Velden AWG, van ‘t Riet M, Dijkstra N, Bogler O, Goulioti T, Hilsenbeck S, Ruddy KJ, Wolff A, van Deurzen CHM, Martens J, Bartlett JMS, Aalders K, Tryfonidis K, Cardoso F.

  • Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04

Time: Friday, December 8, 7:00 am – 9:00 am
Location: PD7-12
Authors: Martens JWM, Sieuwerts A, Ponchet C, Smid M, de Weerd V, Slaets L, Piper T, van Deurzen CHM, Schroder CP, Stangle C, Kloosterman W, van Leeuwen-Stok E, Nilsson C, Vermeij J, Peeters S, Goulioti T, Nowaczyk M, Aebi S, Rubio IT, Kelly C, Bayani J, Porter P, Murray M, Hudis C, Middleton L, Korde L, Ruddy K, Winer E, Bogler O, van den Weyngaert D, dal Lago L, Fraser J, Benstead K, van Asperen C, Linderholm B, Hedenfalk I, Tryfonidis K, Giordano S, Bartlett J, Cardoso F.

  • Young age and the risk of disease recurrence as assessed by the 70-gene signature: an analysis from the EORTC 10041/BIG 03-04 MINDACT trial

Time: Wednesday, December 6, 5:00 pm – 7:00 pm
Location: P1-07-08
Authors: Aalders K, Genbrugge E, Poncet C, Kuijer A, Pistilli B, Piccart M, Tryfonidis K, van Dalen T, Cardoso F, van ‘t Veer L, Rutgers E.

  • Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer: Results from the EORTC 75111- 10114 ETF/BCG randomized phase II study

Time: Thursday, December 7, 7:00 am – 9:00 am
Location: PD3-09
Authors: Wildiers H, Tryfonidis K, dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Aalders K, Meulemans B, Litiere S, Touati N, Cardoso F, Brain E.

Back to news list

Related News

  • EORTC calls for a balanced and feasible European Health Data Space (EHDS)

  • Professor Benjamin Besse becomes President of EORTC

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026